Related references
Note: Only part of the references are listed.Burden of Pancreatic Cancer: From Epidemiology to Practice
Natalia Khalaf et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2021)
Liquid Biopsy in Pancreatic Cancer: Are We Ready to Apply It in the Clinical Practice?
Victoria Heredia-Soto et al.
CANCERS (2021)
Single-cell analysis of pancreatic ductal adenocarcinoma identifies a novel fibroblast subtype associated with poor prognosis but better immunotherapy response
Yu Wang et al.
CELL DISCOVERY (2021)
Cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
BRCA Mutations in Pancreas Cancer: Spectrum, Current Management, Challenges and Future Prospects
Winston Wong et al.
CANCER MANAGEMENT AND RESEARCH (2020)
Liquid Biopsy as Novel Tool in Precision Medicine: Origins, Properties, Identification and Clinical Perspective of Cancer's Biomarkers
Diego Fernandez-Lazaro et al.
DIAGNOSTICS (2020)
Current Status of Circulating Tumor DNA Liquid Biopsy in Pancreatic Cancer
Miles W. Grunvald et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma
Yunzhen Qian et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group
F. Mosele et al.
ANNALS OF ONCOLOGY (2020)
Next-Generation Sequencing in Pancreatic Cancer
Gong-Qing Shen et al.
PANCREAS (2019)
Targeting FLT3 mutations in AML: review of current knowledge and evidence
Naval Daver et al.
LEUKEMIA (2019)
The growing landscape of FLT3 inhibition in AML
Catherine C. Smith
Hematology-American Society of Hematology Education Program (2019)
Liquid biopsy in pancreatic cancer: the beginning of a new era
Dipesh Kumar Yadav et al.
Oncotarget (2018)
Proteomic Identification of FLT3 and PCBP3 as Potential Prognostic Biomarkers for Pancreatic Cancer
Marija Ger et al.
ANTICANCER RESEARCH (2018)
Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution
Christopher Abbosh et al.
NATURE (2017)
KRAS mutations in blood circulating cell-free DNA: a pancreatic cancer case-control study
Florence Le Calvez-Kelm et al.
ONCOTARGET (2016)
A prospective randomised phase-II trial with gemcitabine versus gemcitabine plus sunitinib in advanced pancreatic cancer
L. Bergmann et al.
EUROPEAN JOURNAL OF CANCER (2015)
Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma
Spring Holter et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Hepatocyte Nuclear Factor 1A (HNF1A) as a Possible Tumor Suppressor in Pancreatic Cancer
Zhaofan Luo et al.
PLOS ONE (2015)
Tumor suppressor functions of Dnmt3a and Dnmt3b in the prevention of malignant mouse lymphopoiesis
S. L. Peters et al.
LEUKEMIA (2014)
Aberrant DNA methyltransferase expression in pancreatic ductal adenocarcinoma development and progression
Jun Gao et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2013)
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes
Andrew V. Biankin et al.
NATURE (2012)
Application of next-generation sequencing in clinical oncology to advance personalized treatment of cancer
Yan-Fang Guan et al.
CHINESE JOURNAL OF CANCER (2012)
Inhibition of Ras for cancer treatment: the search continues
Antonio T. Baines et al.
FUTURE MEDICINAL CHEMISTRY (2011)
Expression of DNMT1 and DNMT3a Are Regulated by GLI1 in Human Pancreatic Cancer
ShanShan He et al.
PLOS ONE (2011)
Distant metastasis occurs late during the genetic evolution of pancreatic cancer
Shinichi Yachida et al.
NATURE (2010)
Research electronic data capture (REDCap)-A metadata-driven methodology and workflow process for providing translational research informatics support
Paul A. Harris et al.
JOURNAL OF BIOMEDICAL INFORMATICS (2009)
Follow-Up Study of K-ras Mutations in the Plasma of Patients With Pancreatic Cancer Correlation With Clinical Features and Carbohydrate Antigen 19-9
Jan Daebritz et al.
PANCREAS (2009)
The prevalence of BRCA2 mutations in familial pancreatic cancer
Fergus J. Couch et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2007)
FGFR4 overexpression in pancreatic cancer is mediated by an intronic enhancer activated by HNF1α
RNH Shah et al.
ONCOGENE (2002)
Share Paper
